Table 2 Distribution of underlying factors in individuals with single or recurrent episodes of erysipelas

Age, years (95% CI)

58.0 (56.1-60.0)

61.5 (58.6-64.1)

1.1 (1.0-1.2)

0.05

Gender, % male

211 (58.6)

75 (52.8)

0.8 (0.5-1.2)

0.36

Local operation

71 (19.7)

46 (32.4)

2.0 (1.3-3.0)

<0.01

CABG¹⁾

16 (4.4)

13 (9.2)

2.2 (1.0-4.6)

0.05

Localization

Lower limbs

231 (64.2)

111 (78.2)

1 (reference)

<0.01

Upper limbs

60 (16.7)

15 (10.6)

0.5 (0.3-0.9)

Thorax/trunc

24 (6.7)

11 (7.6)

0.9 (0.4-2.0)

Head/face

45 (12.5)

6 (3.5)

0.3 (0.1-0.7)

Skin disease

42 (11.7)

24 (16.9)

1.5 (0.9-2.6)

0.12

Malignancy

53 (14.7)

36 (25.4)

2.0 (1.2-3.7)

<0.01

Radiation therapy

17 (4.7)

11 (7.8)

1.7 (0.8-3.7)

0.19

Immuno-suppressive therapy

36 (14.1)

8 (8.2)

0.5 (0.2-1.2)

0.14

Arterial insufficiency

13 (3.6)

8 (5.6)

1.6 (0.6-3.9)

0.32

Venous insufficiency¹⁾

16 (4.4)

16 (11.3)

2.7 (1.3-5.6)

<0.01

Lymphedema

8 (2.2)

19 (13.4)

6.8 (2.9-15.9)

<0.01

Diabetes mellitus

52 (14.4)

25 (17.6)

1.3 (0.8-2.1)

0.38

Polyneuropathy

11 (3.1)

4 (2.8)

0.9 (0.3-2.9)

0.89

Vascular disease

62 (17.2)

24 (16.9)

1.0 (0.6-1.6)

0.93

COPD

22 (6.1)

3 (2.1)

0.3 (0.1-1.1)

0.09

Systemic inflammatory disease

16 (4.5)

4 (2.8)

0.6 (0.2-1.8)

0.41

Wound

176 (49.0)

53 (37.3)

0.6 (0.4-0.9)

0.02

Toe web intertrigo¹⁾

10 (2.8)

8 (5.6)

2.1 (0.8-5.4).

0.13

Severe obesitas

1 (0.3)

4 (2.8)

10.4 (1.2-93.9)

0.04

Liver disease

9 (2.5)

4 (2.8)

1.1 (0.3-3.7)

0.84